Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy

SN Byrareddy, J Arthos, C Cicala, F Villinger, KT Ortiz… - Science, 2016 - science.org
SN Byrareddy, J Arthos, C Cicala, F Villinger, KT Ortiz, D Little, N Sidell, MA Kane, J Yu…
Science, 2016science.org
Antiretroviral drug therapy (ART) effectively suppresses replication of both the
immunodeficiency viruses, human (HIV) and simian (SIV); however, virus rebounds soon
after ART is withdrawn. SIV-infected monkeys were treated with a 90-day course of ART
initiated at 5 weeks post infection followed at 9 weeks post infection by infusions of a
primatized monoclonal antibody against the α4β7 integrin administered every 3 weeks until
week 32. These animals subsequently maintained low to undetectable viral loads and …
Antiretroviral drug therapy (ART) effectively suppresses replication of both the immunodeficiency viruses, human (HIV) and simian (SIV); however, virus rebounds soon after ART is withdrawn. SIV-infected monkeys were treated with a 90-day course of ART initiated at 5 weeks post infection followed at 9 weeks post infection by infusions of a primatized monoclonal antibody against the α4β7 integrin administered every 3 weeks until week 32. These animals subsequently maintained low to undetectable viral loads and normal CD4+ T cell counts in plasma and gastrointestinal tissues for more than 9 months, even after all treatment was withdrawn. This combination therapy allows macaques to effectively control viremia and reconstitute their immune systems without a need for further therapy.
AAAS